Key result
Tirofiban yields ~2.1-fold higher odds of excellent functional recovery in anterior circulation ischemic stroke.
Why the study?
The authors aimed to evaluate neuroimaging characteristics and their clinical significance to guide tirofiban treatment in patients with acute ischemic stroke who did not undergo early recanalization treatments.
Does tirofiban improve excellent functional outcomes at 90 days in adults with mild-to-moderate acute ischemic stroke based on specific neuroimaging features?
Does tirofiban improve excellent functional outcomes at 90 days in adults with mild-to-moderate acute ischemic stroke based on specific neuroimaging features?
Tirofiban significantly improves 90-day functional outcomes in acute ischemic stroke patients with anterior circulation stroke or severe vascular stenosis, but not in those with posterior circulation stroke.
Answers are grounded in this paper and cite their sources.
Subgroup benefit may exist with tirofiban; leaves open targeted use but should not change practice pending confirmation.
In a previously published clinical trial, we demonstrated that tirofiban was effective and safe in acute ischemic stroke (AIS) patients who did not undergo early recanalization treatments. We aimed to evaluate neuroimaging characteristics and their clinical significance to guide tirofiban treatment. In this post hoc analysis, location of infarcts (anterior circulation stroke [ACS] vs. posterior circulation stroke [PCS]), degree of cerebral artery stenosis (≤69% vs. ≥70% or occlusion), total infarct volume, and ASPECTS were used to predict the treatment effects of tirofiban, defined as the proportions of excellent and favorable functional outcome (modified Rankin Scale [mRS] score of 0-1, 0-2) at 90 days. ACS patients were more likely to achieve excellent (OR 2.08; 95% CI 1.25-3.45; p = 0.004) and favorable functional outcome (OR 2.28; 95% CI 1.24-4.22; p = 0.008) when treated with tirofiban. However, there was no significant difference in PCS patients between tirofiban and the control group. For patients with severe stenosis (≥70% or occlusion), tirofiban treatment improved the proportion of good outcomes (OR 2.84; 95% CI 1.44-5.60; p = 0.002 for mRS 0-1; OR 2.42; 95% CI 1.22-4.77; p = 0.011 for mRS 0-2). Meanwhile, we found that tirofiban improved outcome in patients with ASPECTS 8-10 and was independent of total infarct volume. These findings support the hypothesis that patients with ACS and severe stenosis may be recommended for tirofiban treatment, which can be predicted independent of total infarct volume.
No takes yet. Share an insight, caveat, or question.
Han et al. (2023) studied Acute ischemic stroke (n=357). Tirofiban vs. Regular treatment (aspirin 100 mg per day) was evaluated on Excellent functional outcome (mRS 0-1) at 90 days in patients with anterior circulation stroke (ACS) (OR 2.08, 95% CI 1.25-3.45, p=0.004). In a post hoc analysis, tirofiban increased the odds of achieving an excellent functional outcome at 90 days in acute ischemic stroke patients with anterior circulation involvement or severe vessel stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: